Global private equity and venture capital news and research

London pension fund major appoints GSK director Robert Vandersluis to board

11 Nov 2013

Robert Vandersluis LPFAUK government pension major the London Pensions Fund Authority has brought in GlaxoSmithKline’s director of global pension investments Robert Vandersluis as a non-executive director and board member.

Vandersluis manages a large derivative and investment portfolio at GSK as well as providing strategic advice to its trustees for pensions fund in Europe, the US and Japan.

He previously held senior positions at Affinity Sutton Group and Ford Credit Europe Bank, and has served on the boards of five organisations including The Pensions Trust.

LPFA chairman Edi Truell said, “One of the LPFA’s priorities at present is to build our in-house and board capabilities, reducing the need for external advisers.

“Robert has achieved an enormous amount in his career so far and will further enhance our credentials in asset and liability management and treasury management.

“We are delighted to be welcoming someone with his talent, expertise and passion to our board.”

Michael Cassidy retired from the board at the end of September after completing his second and final term, LPFA added.

The pension fund grew by £427m during 2012-13 according to its annual report released in September, bringing its total size to £4.6bn.

It said that despite challenging market conditions the soon-to-be-merged Active and Pensioner sub-funds both saw strong growth of 12.6 per cent and 9.6 per cent respectively, outperforming their set benchmarks over one and three years.

LPFA said the performance was positively impacted by a strategic decision to remove an interest rate hedge, which harvested a benefit of £178m.

Copyright © 2013 AltAssets

Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: WeWork 4001, 1 Fore Street, London, EC2Y 5EJ
Content is © AltAssets 2000-2016